Journal Article DZNE-2021-00649

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Natural History of Polymerase Gamma-Related Ataxia.

 ;  ;  ;  ;  ;  ;  ;

2021
Wiley New York, NY

Movement disorders 36(11), 2642-2652 () [10.1002/mds.28713]

This record in other databases:    

Please use a persistent id in citations: doi:

Abstract: Mutations in the mitochondrial DNA polymerase gamma are causing a wide phenotypic spectrum including ataxia as one of the most common presentations.The objective of this study was to determine the course of disease of polymerase gamma-related ataxia.In a prospective natural history study, we assessed 24 adult ataxia patients with biallelic polymerase gamma mutations for (1) severity of cerebellar dysfunction using the Scale for the Assessment and Rating of Ataxia score, (2) presence of nonataxia signs using the Inventory of Non-Ataxia Symptoms, (3) gray- and white-matter changes in brain MRI, and (4) findings in nerve conduction studies.Assessment included follow-up visits up to 11.6 years. The Scale for the Assessment and Rating of Ataxia showed a mean annual increase of 1.02 ± 0.78 points/year. Disease progression was faster in patients with age at onset ≤ 30 years (1.5 Scale for the Assessment and Rating of Ataxia points/year) than with later onset (0.5 points/year); P = 0.008. The Inventory of Non-Ataxia Symptoms count increased by 0.30 ± 0.4 points/year. External ophthalmoplegia, brain stem oculomotor signs, areflexia, and sensory deficits were the most common nonataxic features. On MRI cerebellar atrophy was mild. T2 signal alterations affected mostly cerebellar white matter, middle cerebellar peduncles, thalamus, brain stem, and occipital and frontal white matter. Within 4 years, progression was primarily observed in the context of repeated epileptic seizures. Nerve conduction studies revealed axonal sensory peripheral neuropathy with mild motor nerve involvement. Exploratory sample size calculation implied 38 patients per arm as sufficient to detect a reduction of progression by 50% in hypothetical interventions within a 1-year trial.The results recommend the Scale for the Assessment and Rating of Ataxia as a primary outcome measure for future interventional trials in polymerase gamma-related ataxia. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Keyword(s): Adult (MeSH) ; Ataxia: complications (MeSH) ; Ataxia: diagnostic imaging (MeSH) ; Cerebellar Ataxia (MeSH) ; DNA Polymerase gamma: genetics (MeSH) ; Humans (MeSH) ; Magnetic Resonance Imaging (MeSH) ; Prospective Studies (MeSH) ; POLG ; ataxia ; natural history ; polymerase gamma

Classification:

Contributing Institute(s):
  1. Parkinson Genetics (AG Gasser 1)
Research Program(s):
  1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)

Appears in the scientific report 2021
Database coverage:
Medline ; Creative Commons Attribution-NonCommercial CC BY-NC 4.0 ; OpenAccess ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; DEAL Wiley ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 5 ; JCR ; NationallizenzNationallizenz ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Document types > Articles > Journal Article
Institute Collections > TÜ DZNE > TÜ DZNE-AG Gasser
Full Text Collection
Public records
Publications Database

 Record created 2021-08-12, last modified 2024-03-20


OpenAccess:
Download fulltext PDF Download fulltext PDF (PDFA)
External link:
Download fulltextFulltext
Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)